Vaccine Adjuvants Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024 - 2030)

Chapter 1. Research Scope

1.1. Research Objectives

1.2. Market Definition

1.3. Analysis Period

1.4. Market Size Breakdown by Segments

1.4.1. Market size breakdown, by product

1.4.2. Market size breakdown, by disease type

1.4.3. Market size breakdown, by route of administration

1.4.4. Market size breakdown, by application

1.4.5. Market size breakdown, by region

1.5. Market Data Reporting Unit

1.5.1. Value

1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.1.1. Paid

2.1.2. Unpaid

2.1.3. P&S Intelligence database

2.2. Primary Research

2.3. Market Size Estimation

2.4. Data Triangulation

2.5. Currency Conversion Rates

2.6. Assumptions for the Study

2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics

5.1.1. Trends

5.1.2. Drivers

5.1.3. Restraints/challenges

5.1.4. Impact analysis of drivers/restraints

5.2. Impact of COVID-19

5.3. Porter’s Five Forces Analysis

5.3.1. Bargaining power of buyers

5.3.2. Bargaining power of suppliers

5.3.3. Threat of new entrants

5.3.4. Intensity of rivalry

5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview

6.2. Market Revenue, by Product (2019–2030)

6.3. Market Revenue, by Disease Type (2019–2030)

6.4. Market Revenue, by Route of Administration (2019–2030)

6.5. Market Revenue, by Application (2019–2030)

6.6. Market Revenue, by Region (2019–2030)

Chapter 7. North America Market

7.1. Overview

7.2. Market Revenue, by Product (2019–2030)

7.3. Market Revenue, by Disease Type (2019–2030)

7.4. Market Revenue, by Route of Administration (2019–2030)

7.5. Market Revenue, by Application (2019–2030)

7.6. Market Revenue, by Country (2019–2030)

Chapter 8. Europe Market

8.1. Overview

8.2. Market Revenue, by Product (2019–2030)

8.3. Market Revenue, by Disease Type (2019–2030)

8.4. Market Revenue, by Route of Administration (2019–2030)

8.5. Market Revenue, by Application (2019–2030)

8.6. Market Revenue, by Country (2019–2030)

Chapter 9. APAC Market

9.1. Overview

9.2. Market Revenue, by Product (2019–2030)

9.3. Market Revenue, by Disease Type (2019–2030)

9.4. Market Revenue, by Route of Administration (2019–2030)

9.5. Market Revenue, by Application (2019–2030)

9.6. Market Revenue, by Country (2019–2030)

Chapter 10. LATAM Market

10.1. Overview

10.2. Market Revenue, by Product (2019–2030)

10.3. Market Revenue, by Disease Type (2019–2030)

10.4. Market Revenue, by Route of Administration (2019–2030)

10.5. Market Revenue, by Application (2019–2030)

10.6. Market Revenue, by Country (2019–2030)

Chapter 11. MEA Market

11.1. Overview

11.2. Market Revenue, by Product (2019–2030)

11.3. Market Revenue, by Disease Type (2019–2030)

11.4. Market Revenue, by Route of Administration (2019–2030)

11.5. Market Revenue, by Application (2019–2030)

11.6. Market Revenue, by Country (2019–2030)

Chapter 12. Competitive Landscape

12.1. List of Market Players and their Offerings

12.2. Competitive Benchmarking of Key Players

12.3. Product Benchmarking of Key Players

12.4. Recent Strategic Developments

Chapter 13. Company Profiles

13.1. GlaxoSmithKline plc.

13.1.1. Business overview

13.1.2. Product and service offerings

13.1.3. Key financial summary

13.2. Dynavax Technologies

13.2.1. Business overview

13.2.2. Product and service offerings

13.2.3. Key financial summary

13.3. Novavax

13.3.1. Business overview

13.3.2. Product and service offerings

13.3.3. Key financial summary

13.4. Agenus Inc.

13.4.1. Business overview

13.4.2. Product and service offerings

13.4.3. Key financial summary

13.5. Croda International plc

13.5.1. Business overview

13.5.2. Product and service offerings

13.5.3. Key financial summary

13.6. Seppic

13.6.1. Business overview

13.6.2. Product and service offerings

13.7. OZ Biosciences

13.7.1. Business overview

13.7.2. Product and service offerings

13.8. Merck KGaA

13.8.1. Business overview

13.8.2. Product and service offerings

13.8.3. Key financial summary

13.9. InvivoGen

13.9.1. Business overview

13.9.2. Product and service offerings

13.10. SPI Pharma

13.10.1. Business overview

13.10.2. Product and service offerings

13.11. Aurorium Holdings LLC

13.11.1. Business overview

13.11.2. Product and service offerings

13.12. EuBiologics Co., Ltd

13.12.1. Business overview

13.12.2. Product and service offerings

13.12.3. Key financial summary

13.13. Phibro Animal Health Corporation

13.13.1. Business overview

13.13.2. Product and service offerings

13.13.3. Key financial summary

13.14. Shionogi & Co., Ltd.

13.14.1. Business overview

13.14.2. Product and service offerings

13.14.3. Key financial summary

Chapter 14. Appendix

14.1. Abbreviations

14.2. Sources and References

14.3. Related Reports